A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT06586112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.
Study identification
- NCT ID
- NCT06586112
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 912 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 24, 2024
- Primary completion
- Sep 18, 2025
- Completion
- Nov 19, 2025
- Last update posted
- Aug 9, 2026
2024 – 2025
United States locations
- U.S. sites
- 55
- U.S. states
- 21
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alliance Dermatology | Phoenix | Arizona | 85032 | — |
| Scottsdale Clinical Trials | Scottsdale | Arizona | 85260 | — |
| Northwest Arkansas Clinical Trials Center (NWACTC), PLLC | Rogers | Arkansas | 72758-8600 | — |
| Exalt Clinical Research | Chula Vista | California | 91910 | — |
| California Dermatology & Clinical Research Institute | Encinitas | California | 92024-7700 | — |
| First OC Dermatology Research Inc | Fountain Valley | California | 92708 | — |
| Marvel Clinical Research, LLC | Huntington Beach | California | 92647 | — |
| Sunwise Clinical Research, LLC | Lafayette | California | 94549 | — |
| Wallace Medical Group Inc | Los Angeles | California | 90056 | — |
| Northridge Clinical Trials - Elite Clinical Network | Northridge | California | 91325 | — |
| Pasadena Clinical Trials | Pasadena | California | 91101 | — |
| Therapeutics Clinical Research | San Diego | California | 92123 | — |
| Unison Clinical Trials/ Shahram Jacobs MD | Sherman Oaks | California | 91403-1814 | — |
| Olive View - UCLA Education & Research Institute | Sylmar | California | 91342 | — |
| California Dermatology Institute - Thousand Oaks | Thousand Oaks | California | 91320-2130 | — |
| Clearlyderm Dermatology - West Boca Raton | Boca Raton | Florida | 33428 | — |
| Driven Clinical Research | Coral Gables | Florida | 33134 | — |
| Jacksonville Center for Clinical Research | Jacksonville | Florida | 32216 | — |
| Glick Skin Institute - Margate | Margate | Florida | 33063-7011 | — |
| San Marcus Research Clinic, Inc - Miami | Miami Lakes | Florida | 33014 | — |
| Savin Medical Group LLC | Miami Lakes | Florida | 33014 | — |
| Oceanic Research Group | North Miami Beach | Florida | 33169 | — |
| LENUS Research | Sweetwater | Florida | 33172 | — |
| Caban Skin Institute | Tampa | Florida | 33607 | — |
| ForCare Medical Center | Tampa | Florida | 33613-1244 | — |
| Skin Care Physicians of Georgia - Warner Robins | Macon | Georgia | 31217 | — |
| MetroMed Clinical Trials | Chicago | Illinois | 60614-3625 | — |
| Arlington Dermatology | Rolling Meadows | Illinois | 60008 | — |
| NorthShore Medical Group - Dermatology - Skokie | Skokie | Illinois | 60077-1049 | — |
| Dundee Dermatology | West Dundee | Illinois | 60118 | — |
| Dawes Fretzin Clinical Research Group | Columbus | Indiana | 47201 | — |
| The South Bend Clinic | South Bend | Indiana | 46617 | — |
| Equity Medical - Bowling Green | Bowling Green | Kentucky | 42104 | — |
| Velocity Clinical Research at The Dermatology Clinic, Baton Rouge | Baton Rouge | Louisiana | 70808 | — |
| Tulane University School of Medicine | New Orleans | Louisiana | 70112 | — |
| MetroBoston Clinical Partners | Brighton | Massachusetts | 02135 | — |
| Cleaver Dermatology | Kirksville | Missouri | 63501-5362 | — |
| OptiSkin | New York | New York | 10128-0724 | — |
| The Ohio State University Wexner Medical Center (OSUWMC) - OSU Dermatology East - Columbus | Gahanna | Ohio | 43230-5317 | — |
| Dermatologists of Southwestern Ohio, LLC | Mason | Ohio | 45040-4520 | — |
| Unity Clinical Research (UCR) | Oklahoma City | Oklahoma | 73118 | — |
| Velocity Clinical Research, Medford | Medford | Oregon | 97504 | — |
| Oregon Medical Research Center | Portland | Oregon | 97201 | — |
| Paddington Testing Company Inc. | Philadelphia | Pennsylvania | 19103 | — |
| UPMC Department of Dermatology | Pittsburgh | Pennsylvania | 15213 | — |
| Health Concepts | Rapid City | South Dakota | 57702-9208 | — |
| Discover Dermatology, LLC d/b/a Goodlettsville Dermatology Research | Goodlettsville | Tennessee | 37072-2301 | — |
| Discover Dermatology, LLC d/b/a Cumberland Skin Center for Clinical Research under Objective Health | Hermitage | Tennessee | 37076 | — |
| UT Health Houston Department of Dermatology | Bellaire | Texas | 77401 | — |
| Studies in Dermatology, LLC | Cypress | Texas | 77429 | — |
| Reveal Research Institute | Frisco | Texas | 75033 | — |
| Center for Clinical Studies - Texas Medical Center | Houston | Texas | 77004 | — |
| Austin Institute for Clinical Research - Houston | Houston | Texas | 77056 | — |
| University of Utah Health Care - Midvalley Health Center | Murray | Utah | 84107 | — |
| Frontier Dermatology | Mill Creek | Washington | 98012 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06586112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06586112 live on ClinicalTrials.gov.